Abstract
In recent times, laser treatment combined with intravitreal bevacizumab (Avastin) has been used rarely as early investigations to treat patients with aggressive posterior retinopathy of prematurity (ROP). We describe choroidal ruptures that were documented at 10 weeks after this combined treatment in a preterm infant born at 28 weeks gestation with a birth weight of 1190 g. Aggressive posterior ROP was diagnosed at the age of 6 weeks. Initial treatment included bilateral laser ablation, followed immediately by intravitreal bevacizumab (IVB, 0.75 mg) in the right eye. On day 5, a remarkable regression of plus sign and fibrovascular proliferation was noted only in the right eye. At this point, additional laser treatment combined with IVB was given in the left eye, which dramatically resolved plus disease and neovascularization. At 10 weeks after IVB in the left eye, two sites of choroidal ruptures were revealed along the posterior edges of laser scars. There was no evidence of choroidal neovascularization associated with the choroidal ruptures. Choroidal rupture may occur shortly after laser ablation plus IVB treatment for aggressive posterior ROP. This occurrence requires recognition to determine whether it is actually related to the treatment. Long-term follow-up is important for understanding the nature and progression of this potentially serious complication.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Chung EJ, Kim JH, Ahn HS, Koh HJ . Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 2007; 245: 1727–1730.
Kusaka S, Shima C, Wada K, Arahori H, Shimojyo H, Sato T et al. Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study. Br J Ophthalmol 2008; 92: 1450–1455.
Quiroz-Mercado H, Martinez-Castellanos MA, Hernandez-Rojas ML, Salazar-Teran N, Chan RV . Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity. Retina 2008; 28: S19–S25.
Honda S, Hirabayashi H, Tsukahara Y, Negi A . Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 2008; 246: 1061–1063.
Atmaca LS, Yilmaz M . Changes in the fundus caused by blunt ocular trauma. Ann Ophthalmol 1993; 25: 447–452.
Estafanous MF, Seeley M, Traboulsi EI . Choroidal rupture associated with forceps delivery. Am J Ophthalmol 2000; 129: 819–820.
Park P, Eagle Jr RC, Tasman WS . Diode laser photocoagulation for retinopathy of prematurity: a histopathologic study. Ophthalmic Surg Lasers 2001; 32: 63–66.
Baba T, Grebe R, Hasegawa T, Bhutto I, Merges C, McLeod DS et al. Maturation of the fetal human choriocapillaris. Invest Ophthalmol Vis Sci 2009; 50: 3503–3511.
Marneros AG, Fan J, Yokoyama Y, Gerber HP, Ferrara N, Crouch RK et al. Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. Am J Pathol 2005; 167: 1451–1459.
Yi X, Mai LC, Uyama M, Yew DT . Time-course expression of vascular endothelial growth factor as related to the development of the retinochoroidal vasculature in rats. Exp Brain Res 1998; 118: 155–160.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Atchaneeyasakul, LO., Trinavarat, A. Choroidal ruptures after adjuvant intravitreal injection of bevacizumab for aggressive posterior retinopathy of prematurity. J Perinatol 30, 497–499 (2010). https://doi.org/10.1038/jp.2009.166
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/jp.2009.166
Keywords
This article is cited by
-
Anti-secretogranin III therapy of oxygen-induced retinopathy with optimal safety
Angiogenesis (2019)
-
Serial evaluation of retinal vascular changes in infants treated with intravitreal bevacizumab for aggressive posterior retinopathy of prematurity in zone I
Eye (2016)
-
Pharmakologische Therapie der Frühgeborenenretinopathie
Der Ophthalmologe (2011)
-
Pharmakologische Therapie der Frühgeborenenretinopathie
Spektrum der Augenheilkunde (2011)